Oncology Co. Boosts Balance Sheet By $1B With EQRx Buy
Clinical-stage oncology company Revolution Medicines Inc., advised by Latham & Watkins LLP, said Tuesday it plans to purchase biopharmaceutical company EQRx Inc., advised by Goodwin Procter LLP, in an all-stock deal...To view the full article, register now.
Already a subscriber? Click here to view full article